Autolus Therapeutics (AUTL) Net Equity Issued and Repurchased (2018 - 2024)

Autolus Therapeutics (AUTL) has reported Net Equity Issued and Repurchased for 6 consecutive years, with $550.0 million the latest figure, recorded in Q1 2024.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $550.0 million in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $550.0 million (changed N/A YoY) and the FY2024 annual result came in at $550.0 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased improved to $550.0 million in Q1 2024 per AUTL's latest filing, from $163.9 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for AUTL reached as high as $550.0 million in Q1 2024 and fell as low as -$356000.0 in Q3 2021.
• A 4-year average of $103.9 million and a median of $40.1 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2020 — Net Equity Issued and Repurchased surged 1857650.0% — and 2021, when it plunged 483.61%.
• Year by year, Net Equity Issued and Repurchased stood at $5.8 million in 2020, then jumped by 1786.48% to $109.4 million in 2021, then soared by 49.81% to $163.9 million in 2022, then surged by 235.65% to $550.0 million in 2024.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $550.0 million, $163.9 million, and $109.4 million for Q1 2024, Q4 2022, and Q4 2021 respectively.